Vercirnon is an orally bioavailable selective antagonist of the CCR9 chemokine receptor (IC50 values 5.4 nM and 3.4 nM for CCR9-mediated Ca2+ mobilization and chemotaxis on Molt-4 cells, respectively). Based on studies of the crystal structure, vercirnon binds to the intracellular side of the receptor, exerting allosteric antagonism and preventing G-protein coupling. Vercirnon was developed for treatment of inflammatory bowel disease, including Crohn's disease and celiac disease.

KEYWORDS: Vercirnon | supplier | CCR9 antagonist | GSK-1605786 | CCX282-B | Traficet-EN | GSK1605786 | GSK 1605786 | CCX282B | CCX282 B | Traficet EN | CAS [698394-73-9] |  Chemokine | Chemokine | Antagonist | Receptors | Coeliac disease | Crohn's disease | Coeliac | Crohn